Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery

March 1, 2025

The "Optimizing Immuno-Oncology: Innovations in ICI Delivery," is an accredited continuing education activity tailored for oncology providers, medical oncologists, fellows, advanced practice providers, pharmacists, and nurses. Designed to address evolving approaches in immune checkpoint inhibitor (ICI) administration, the program focuses on both intravenous (IV) and subcutaneous (SC) delivery methods across multiple tumor types. This program provides healthcare providers with insights into integrating SC ICI administration into practice, selecting appropriate treatment plans, and managing adverse events effectively. Emphasizing a multidisciplinary approach, participants will gain practical tools to improve clinic efficiency, patient adherence, and safety, enhancing patient outcomes in immuno-oncology.

Target Audience

  • Medical Oncologists
  • Fellows
  • Advanced Practice Providers
  • Pharmacists
  • Nurses

Organizing Committee

Conference Director:

Binay Shah, MD, MHA - Binaytara Foundation

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Evaluate the benefits and limitations of IV versus SC administration of immune checkpoint inhibitors across diverse tumor types. 
  • Analyze current evidence on the efficacy, safety, and pharmacokinetics of SC versus IV ICIs in managing patients with cancer.
  • Integrate SC ICI administration into practice through multidisciplinary team approaches that enhance efficiency and patient experience.
  • Implement strategies to monitor and manage adverse events associated with SC ICIs to ensure patient safety and improve adherence.

You may also be interested in

Summit on Cancer Health Disparities (SCHD25)

The Summit on Cancer Health Disparities 2025 (SCHD25) is a premier annual event focused on addressing cancer health disparities. The conference serves to bridge research and practice, offering practical strategies to improve cancer care delivery and outcomes.
Course summary
Available credit: 
  • 1.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 1.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 1.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.00 Contact Hours.
Course opens: 
01/06/2025
Course expires: 
04/02/2025
Event starts: 
03/01/2025 - 7:00am PST
Event ends: 
03/01/2025 - 8:10am PST
Cost:
$0.00
Add to calendar: 

Saturday, March 1, 2025

All times are listed in Pacific Time (PST)

07:00 AM – 07:10 AM Welcome

07:10 AM – 07:30 AM Innovations in ICI Administration – Latest Advances and Implications for Practice - Shailender Bhatia, MD

07:30 AM – 07:50 AM Comparing IV and SC Administration of ICIs – Clinical Evidence and Practical Considerations - Petros Grivas, MD, PhD

07:50 AM – 8:10 AM Q&A 

08:10 AM Adjourn 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Speaker/Topic Presenter(s)

Petros Grivas

has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Professional Services) with Seattle Genetics;.
has a financial relationship (Professional Services) with Astellas Pharma;.
has a financial relationship (Professional Services) with Lucence Health;.
has a financial relationship (Professional Services) with CG Oncology;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Grant Or Contract) with QED Therapeutics;.
has a financial relationship (Grant Or Contract) with G1 Therapeutics;.
has a financial relationship (Grant Or Contract) with ALX Oncology;.
has a financial relationship (Professional Services) with EMD Serano;.
has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Professional Services) with Fresenius Kabi;.
has a financial relationship (Professional Services) with Aadi Biosciences;.
has a financial relationship (Professional Services) with Asieris Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with EMD Serano;.
has a financial relationship (Grant Or Contract) with Acrivon Therapeutics;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with BostonGene;.
has a financial relationship (Professional Services) with G1 Therapeutics;.
has a financial relationship (Professional Services) with Immunity Bio;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Mirati Therapeutics;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Gilead Sciences;.
has a financial relationship (Professional Services) with PureTech;.
has a financial relationship (Professional Services) with Strata Oncology;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with GlaxoSmithKline;.
has a financial relationship (Grant Or Contract) with Gilead Sciences;.
Disclosure link: 
Company Information

Acknowledgement of Commercial Support

This activity is supported with an Independent Medical Education Grant from Merck.

Available Credit

  • 1.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 1.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 1.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

Price

Cost:
$0.00
Please login or register to take this course.

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity via Zoom, and completion of pre & post tests as well as course evaluations.

Refund Policy 

This activity is free for all healthcare providers who are not employees of an ineligible entity.

No refunds will be issued if you are unable to attend the live meeting after enrollment.

Required Hardware/software

This activitywill be held virtually on Zoom. You will need access to internet and a hardware such as a laptop or desktop computer or a mobile device with Zoom application installed.

For best audio-visual experience, please update your Zoom application before joining the meeting.